Physician profile
Chandni Patel
NPI 1790322345
$112,828.84
in general payments reported to CMS, 2019-2025
32 companies · $26K in 2025
The $26K reported for 2025 was more than what 99% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,242 · 2022: $2,790 · 2023: $33K · 2024: $50K · 2025: $26K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $71K · Consulting Fee: $15K · Travel and Lodging: $13K · Food and Beverage: $9,518 · Education: $584.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $71,494.00 |
| Consulting Fee | $14,574.50 |
| Travel and Lodging | $12,626.27 |
| Food and Beverage | $9,518.39 |
| Education | $583.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $89,030.89 | 2021-2025 | Tremfya, Stelara, Simponi |
| Arcutis Biotherapeutics, INC. | $8,019.05 | 2023-2025 | Zoryve |
| Regeneron Healthcare Solutions, INC. | $6,559.38 | 2021-2024 | Dupixent, Libtayo |
| Abbvie INC. | $3,811.05 | 2021-2025 | |
| Genzyme Corporation | $686.65 | 2021-2025 | |
| Ucb, INC. | $510.73 | 2023-2025 | Bimzelx |
| E.R. Squibb & Sons, L.L.C. | $472.22 | 2022-2025 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $442.34 | 2021-2025 | Winlevi, Absorica Ld, Ilumya |
| Incyte Corporation | $439.60 | 2021-2025 | Opzelura |
| Novartis Pharmaceuticals Corporation | $410.69 | 2021-2025 | |
| Lilly USA, LLC | $389.74 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Leo Pharma INC. | $256.59 | 2021-2025 | Adbry |
| Medimetriks Pharmaceuticals, INC. | $250.00 | 2023 | |
| Amgen INC. | $244.43 | 2021-2025 | Otezla, Otezla |
| Pfizer INC. | $226.15 | 2022-2024 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $176.69 | 2022-2024 | Vtama |
| Journey Medical Corporation | $171.59 | 2023 | |
| Galderma Laboratories, L.P. | $136.26 | 2021-2025 | Aklief, Oracea, Nemluvio |
| Almirall LLC | $103.40 | 2022-2023 | Seysara |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $97.54 | 2021-2023 | Arazlo |
| Sanofi-Aventis U.S. LLC | $69.99 | 2023 | |
| Viiv Healthcare Company | $67.41 | 2024 | Apretude |
| Epi Health, LLC | $56.87 | 2021-2022 | |
| Janssen Scientific Affairs, LLC | $36.86 | 2022 | |
| Nabriva Therapeutics, Plc | $35.70 | 2022 | |
| Strata Skin Sciences, INC. | $26.74 | 2021-2024 | Xtrac |
| Dermira, INC. | $25.54 | 2021 | |
| Smith+Nephew, INC. | $17.70 | 2023 | Collagenase Santyl |
| Genentech USA, INC. | $14.95 | 2021 | |
| Organon LLC | $14.72 | 2025 | Vtama |
| Nobelpharma America, LLC | $14.30 | 2023 | |
| Mayne Pharma Commercial LLC | $13.07 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chandni Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.